Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept (Q41167828)

27 September 2017

title

Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept (English)

1 reference

27 September 2017

10

Claire-Anne Siegrist

1 reference

27 September 2017

author name string

Beatris Mastelic Gavillet

1

1 reference

27 September 2017

Lucie Mondoulet

2

1 reference

27 September 2017

Véronique Dhelft

3

1 reference

27 September 2017

Christiane Sigrid Eberhardt

4

1 reference

27 September 2017

Floriane Auderset

5

1 reference

27 September 2017

Hong Thai Pham

6

1 reference

27 September 2017

Jean Petre

7

1 reference

27 September 2017

Paul-Henri Lambert

8

1 reference

27 September 2017

Pierre-Henri Benhamou

9

1 reference

27 September 2017

language of work or name

English

0 references

publication date

9 June 2015

1 reference

27 September 2017

1 reference

27 September 2017

volume

33

1 reference

27 September 2017

issue

30

1 reference

27 September 2017

page(s)

3450-3455

1 reference

Pertussis vaccine trials in the 1990s

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Pertussis of adults and infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Possible options for new pertussis vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Duration of immunity against pertussis after natural infection or vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Shortcomings of pertussis vaccines: why we need a third generation vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Mutants of pertussis toxin suitable for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Immune surveillance in the skin: mechanisms and clinical consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Transcutaneous vaccines--current and emerging strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

A pilot study of the usefulness and safety of a ready-to-use atopy patch test (Diallertest) versus a comparator (Finn Chamber) during cow's milk allergy in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Epicutaneous Immunotherapy Results in Rapid Allergen Uptake by Dendritic Cells through Intact Skin and Downregulates the Allergen-Specific Response in Sensitized Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Langerhans cells promote early germinal center formation in response to Leishmania-derived cutaneous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Mouse and pig models for studies of natural and vaccine-induced immunity to Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Systematic comparison of gene expression between murine memory and naive B cells demonstrates that memory B cells have unique signaling capabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Intrinsic differences in the proliferation of naive and memory human B cells as a mechanism for enhanced secondary immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Antigen-specific memory B cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Nonhuman primate and human challenge models of pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Multiphoton high-resolution 3D imaging of Langerhans cells and keratinocytes in the mouse skin model adopted for epidermal powdered immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Disappearance of epidermal Langerhans cells during PUVA therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

Surface-associated filamentous hemagglutinin induces autoagglutination of Bordetella pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.05.089

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.05.089

1 reference

27 September 2017

1 reference